Avon Funds Breast Cancer Awareness Program for Orthodox Jewish Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

NEW YORK--The Avon Breast Health Access Fund has awarded a grant of $23,961 to Cancer Care for a program to increase awareness of the life-saving benefits of early breast cancer detection among low-income Orthodox Jewish women in New York City. Cancer Care is a nonprofit organization that provides free professional services to people with cancer and their families,

NEW YORK--The Avon Breast Health Access Fund has awarded a grantof $23,961 to Cancer Care for a program to increase awarenessof the life-saving benefits of early breast cancer detection amonglow-income Orthodox Jewish women in New York City. Cancer Careis a nonprofit organization that provides free professional servicesto people with cancer and their families,

The program will serve large enclaves of Orthodox Jewish womenwho, because of language, cultural beliefs, and socioeconomicreasons, receive inadequate health care. These women are not exposedto popular media that have long promoted breast health education.Moreover, because of modesty, the word breast is rarely used inthese communities.

The program will provide free educational seminars on the benefitsof early detection in the Orthodox Jewish communities, locatedprimarily in areas of Brooklyn. The seminars will be given inEnglish, Yiddish, Hebrew, and Russian, and, afterwards, the womenwill be given the opportunity to have a no- or low-cost mammogramand clinical exam.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content